Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 360

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study

Agarwala, Sanjiv S., Kirkwood, John M., Gore, Martin, Dreno, Brigitte, Thatcher, Nicholas, Czarnetski, Beate, Atkins, Michael, Buzaid, Antonio, Skarlos, Dimosthenis, Rankin, Elaine M. · 2004 · Journal of Clinical Oncology

Abstract

Purpose: Temozolomide is a well-tolerated oral alkylating agent with activity in the CNS. A multicenter, open-label, phase II study was conducted to assess the safety and efficacy of temozolomide in patients with brain metastases from metastatic melanoma (MM) who did not require immediate radiotherapy. Patients and Methods: Eligible patients had histologically confirmed MM to the brain, and no prior radiotherapy or radiosurgery for brain metastases. Previously untreated patients received temozolomide at 200 mg/m 2/d × 5 days; previously treated patients received 150 mg/m 2/d × 5 days every 28 days. Treatment continued for 1 year or until disease progression or unacceptable toxicity. Results: Of 151 patients enrolled, 117 had received no prior systemic chemotherapy, and 34 had received prior chemotherapy for MM. Among previously untreated patients, 25% had more than four brain lesions, eight (7%) achieved an objective response (one complete and seven partial), and 34 (29%) had stable disease in brain metastases. Median overall survival was 3.5 months. Among previously treated patients, 21% had more than four brain lesions, one had a partial response, and six (18%) had stable disease in brain metastases. Median overall survival was 2.2 months. Temozolomide was well tolerated, with four (3%) patients discontinuing because of adverse events. Grade 3/4 hematologic toxicities included thrombocytopenia (3%), neutropenia (2%), and leukopenia (1%). Headache (9%) and vomiting (8%) were the most common nonhematologic grade 3/4 adverse events. Conclusion: Temozolomide was well tolerated and demonstrated activity in the treatment of brain metastases from MM. Further evaluation of temozolomide combination therapy is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2004.11.044

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 360

Metadata

Authors
Agarwala, S. S., Kirkwood, J. M., Gore, M., Dreno, B., Thatcher, N., Czarnetski, B., Atkins, M., Buzaid, A., Skarlos, D., & Rankin, E. M.
Venue
Journal of Clinical Oncology
Published
2004-06-01
Volume
22
Issue
11
Pages
2101-2107
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2098405842
Cited by
360
References
19
FWCI
17.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study. https://app.cochat.ai/papers/10.1200/jco.2004.11.044
The paper
Agarwala, S. S., Kirkwood, J. M., Gore, M., Dreno, B., Thatcher, N., Czarnetski, B., Atkins, M., Buzaid, A., Skarlos, D., & Rankin, E. M. (2004). Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.11.044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.